In-silico approach of Fusion Glycoprotein (F) targeted multi-epitope vaccine against Human Respiratory Syncytial Virus (HRSV)

Abstract

"This work created a multi-epitope respiratory syncytial virus vaccine in-silico and simulated its biochemical effectiveness. In-silico investigation selected fusion glycoprotein (F) from envelope proteins of RSV. F protein causes virion-target cell membrane fusion. However, in-silico methodology used several servers, databases, and software such as Vaxijen v2.0 for antigenicity, NetCTL-1.2, NetMHCIIpan 4.0, and Bepipred servers, which were utilized to find epitopes recognized by cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs), and B cells. IFNepitope, IL-4Pred, and IL-10Pred were used to identify epitopes expressed by HTLs. Linkers were used to connect epitopes. Positive findings were found in biochemical analysis of the final proposed vaccine. Positive outcomes were predicted for a range of indicators, including instability index (38.99 as stable), GRAVY score (-0.180), molecular weight (91876.78 dalton), toxicity, antigenicity (0.5810), and allergenicity. Furthermore, acceptable z-score (-9.89) and Ramachandran plot (94.95%) were obtained for the final proposed vaccine via ProSAweb and SWISS-MODEL, respectively. The required outcome was also achieved by homology modeling, molecular docking, and immune response simulation via responsible servers. However, in-silico vaccine discovery for RSV and other diseases may be accelerated"